Published in Pharmacol Res on March 20, 1991
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol (2002) 1.74
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer (1994) 1.55
Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol (2002) 1.29
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol (2006) 1.18
Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer (1999) 1.13
Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J (2001) 1.09
On the possible causes of the release of material absorbing at 260 m-mu by streptomycin treated E. coli cells (K 12 and B). J Antibiot (Tokyo) (1967) 1.08
[Release of nucleotides and integrity of the bacterial membrane (E. coli K 12)]. Antibiotica (1966) 1.06
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol (2005) 1.05
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol (2006) 1.03
Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res (1992) 1.01
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol (1988) 1.01
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol (2007) 0.95
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol (2005) 0.95
Role of galectin-3 as a receptor for advanced glycosylation end products. Kidney Int Suppl (2000) 0.94
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol (2002) 0.94
Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer (1997) 0.94
Lacidipine and josamycin: two new multidrug resistance modulators. Anticancer Res (1995) 0.94
Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Anticancer Res (1996) 0.93
Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Oncology (1997) 0.92
Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity. Eur J Cancer (1994) 0.91
Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer (1996) 0.90
Asymmetrical, agonist-induced fluctuations in local extracellular [Ca(2+)] in intact polarized epithelia. EMBO J (2001) 0.87
The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes (2000) 0.87
Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis. Eur J Clin Chem Clin Biochem (1996) 0.87
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol (2007) 0.86
Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin Cancer Res (2000) 0.86
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. Oncol Rep (2010) 0.85
The glucose clamp reveals an association between adiponectin gene polymorphisms and insulin sensitivity in obese subjects. Int J Obes (Lond) (2006) 0.84
Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer. Anticancer Res (2005) 0.84
Cardiac peroxisomal enzymes and starvation. Free Radic Res Commun (1989) 0.83
Emotional expression and coping style in female breast cancer. Ann Oncol (2007) 0.83
A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother (1993) 0.83
The hypothalamic magnocellular neurosecretory system in developing rats. Eur J Histochem (2001) 0.83
Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas (1997) 0.83
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). Anticancer Drugs (1997) 0.83
The in vitro effect of recombinant erythropoietin on cisdiamminodichloroplatinum-induced inhibition of murine erythroid stem cells. Anticancer Res (1991) 0.82
Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus. Ann Oncol (2007) 0.81
Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. Tumori (1994) 0.81
Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity. Arzneimittelforschung (1971) 0.81
A new variation in the promoter region, the -604 C>T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance. Int J Obes (Lond) (2007) 0.81
Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer: a preliminary study. Anticancer Res (1995) 0.81
Expression of gelatinases (MMP-2, MMP-9) in human articular cartilage. Int J Immunopathol Pharmacol (2013) 0.81
Repair kinetics of DNA, RNA and proteins in the tissues of mice treated with doxorubicin. Arzneimittelforschung (1979) 0.81
The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ (1998) 0.81
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol (2006) 0.81
Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. Eur J Cancer (2011) 0.80
A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res (1994) 0.80
Haemopoietic effects of 7 alpha, 17 beta dimethyltestosterone. Pharmacol Res Commun (1979) 0.80
Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer (1996) 0.79
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother (2005) 0.79
A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer (1993) 0.79
A case of Guillain-Barré syndrome in a patient with non small cell lung cancer treated with chemotherapy. J Chemother (2006) 0.79
Lysosomal alterations in heart and liver of mice treated with doxorubicin. Cancer Chemother Pharmacol (1985) 0.79
The in vitro effect of the antineoplastic agent bryostatin 4 on human hematopoietic progenitor cells. Haematologica (1989) 0.79
Biological characterization of laryngeal squamous-cell carcinoma. Anticancer Res (1996) 0.79
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Ann Oncol (2000) 0.79
Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study. Br J Cancer (1990) 0.79
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer (2006) 0.79
Matrix metalloproteinase-2 matrix metalloproteinase-9 and inducible nitric oxide synthase in oral leukoplakia: immunohistochemistry and RT-PCR analysis. J Biol Regul Homeost Agents (2008) 0.79
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). Ann Oncol (2007) 0.79
Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases. Eur J Surg Oncol (1995) 0.79
Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM). Am J Clin Oncol (1996) 0.78
Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients. Nucleosides Nucleotides Nucleic Acids (2006) 0.78
Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. Eur J Cancer (1994) 0.78
Failure of detection of the tyrosine to histidine substitution at the residue 33 of thymidylate synthase in human colorectal cancer. A preliminary study. Anticancer Res (2001) 0.78
Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications. Med Res Rev (1993) 0.78
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol (2005) 0.78
Hereditary common cancers: molecular and clinical genetics. Anticancer Res (2001) 0.78
Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma. Anticancer Res (1993) 0.78
5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study. J Cancer Res Clin Oncol (1998) 0.78
Expression of gelatinases (MMP-2, MMP-9) and cyclooxygenases (COX-1, COX-2) in some benign salivary gland tumors. Int J Immunopathol Pharmacol (2012) 0.78
Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma. Cancer Invest (1992) 0.78